The humoral response and antibodies against SARS-CoV-2 infection

H Qi, B Liu, X Wang, L Zhang - Nature Immunology, 2022 - nature.com
Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …

Risk factors of severe COVID-19: a review of host, viral and environmental factors

L Zsichla, V Müller - Viruses, 2023 - mdpi.com
The clinical course and outcome of COVID-19 are highly variable, ranging from
asymptomatic infections to severe disease and death. Understanding the risk factors of …

Respiratory syncytial virus epidemiology and clinical severity before and during the COVID-19 pandemic in British Columbia, Canada: a retrospective observational …

MV Paramo, LPL Ngo, B Abu-Raya… - The Lancet Regional …, 2023 - thelancet.com
Background The COVID-19 pandemic has perturbed the seasonality of respiratory syncytial
virus (RSV) infections. However, we lack data on how this impacted the severity of paediatric …

Relative ratios of human seasonal coronavirus antibodies predict the efficiency of cross-neutralization of SARS-CoV-2 spike binding to ACE2

Y Galipeau, V Siragam, G Laroche, E Marion… - …, 2021 - thelancet.com
Background Antibodies raised against human seasonal coronaviruses (sCoVs), which are
responsible for the common cold, are known to cross-react with SARS-CoV-2 antigens. This …

Early human B cell signatures of the primary antibody response to mRNA vaccination

L Kardava, N Rachmaninoff, WW Lau… - Proceedings of the …, 2022 - National Acad Sciences
Messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are highly effective at inducing protective immunity. However, weak antibody …

Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination

ES Geanes, C LeMaster, ER Fraley, S Khanal… - Scientific Reports, 2022 - nature.com
SARS-CoV-2 is a novel betacoronavirus that caused coronavirus disease 2019 and has
resulted in millions of deaths worldwide. Novel coronavirus infections in humans have …

Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2

ME Francis, EB Jansen, A Yourkowski, A Selim… - Nature …, 2023 - nature.com
SARS-CoV-2 variants and seasonal coronaviruses continue to cause disease and
coronaviruses in the animal reservoir pose a constant spillover threat. Importantly …

Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity

L Jia, S Weng, J Wu, X Tian, Y Zhang, X Wang… - Gut …, 2022 - Taylor & Francis
The origins of preexisting SARS-CoV-2 cross-reactive antibodies and their potential impacts
on vaccine efficacy have not been fully clarified. In this study, we demonstrated that S2 was …

Cross-regulation of antibody responses against the SARS-CoV-2 spike protein and commensal microbiota via molecular mimicry

M Bondareva, L Budzinski, P Durek, M Witkowski… - Cell Host & Microbe, 2023 - cell.com
The commensal microflora provides a repertoire of antigens that illicit mucosal antibodies. In
some cases, these antibodies can cross-react with host proteins, inducing autoimmunity, or …

Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination

C Hu, Z Wang, L Ren, Y Hao, M Zhu, H Jiang… - Frontiers in Cellular …, 2022 - frontiersin.org
Purpose This study was conducted in order to properly understand whether prior seasonal
human coronavirus (HCoV) immunity could impact the potential cross-reactivity of humoral …